Key clinical point: GnRH receptor antagonists degarelix and relugolix continue to show safety and effectiveness when used for endocrine therapy in prostate cancer

Major finding: Prostate cancer patients treated with the oral GnRH antagonist relugolix showed a faster return to normal testosterone levels compared to those treated with leuprolide; relugolix also was associated with fewer adverse events than degarelix, although degarelix may be more beneficial for patients with preexisting cardiovascular disease.

Study details: The data come from a review of 33 studies including 9 phase 3 clinical trials.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.